Send your comments and tips to firstname.lastname@example.org
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Nurse at small
Dr. Gwenn Is In
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Short White Coat blogger Jennifer Srygley
Monday, August 13, 2007
Today's Globe: autism triggers, plastic warning, diabetes and bones, bridge inspections, palliative care mission, cystic fibrosis drug deal
Researchers now believe that autism can be caused by genes in combination with environmental triggers. The question is, what are those triggers?
A federal panel of scientists concluded last week that an estrogen-like compound in plastic could be posing some risk to the brain development of babies and children.
As medicine struggles to halt the nation's diabetes epidemic, scientists have found a potential new weapon in the most unlikely place -- the skeleton.
It's a question that's been on a lot of commuters' minds over the last two weeks as they drive over area bridges (left, an inspection last week in Fitchburg): Why didn't engineers know that the Interstate 35 west bridge in Minneapolis was so close to disaster?
Mortality can only, at best, be delayed -- whether from cancer or anything else. So Dr. Bob Buxbaum (right) has devoted himself to palliative care, meaning he helps make a patient's life better once that life is coming to an end.
In Business & Innovation, the Cambridge biotechnology firm FoldRx Pharmaceuticals Inc. will receive $22 million from the Cystic Fibrosis Foundation to develop and commercialize drugs aimed at treating the fatal genetic disease, a disorder of the lungs and digestive system that afflicts 70,000 people worldwide.